Cescon, D. W., Traina, T. A., Schmid, P., Cortés, J., Shao, Z., Saji, S., Jung, K. H., Bachelot, T., Wang, S., Ramírez, E. M., Başaran, G., Chae, Y. S., Stradella, A., Mathiba, R., Chen, S., Battelli, N., Niikura, N., Zhao, K., Maxwell, M. J., Dent, R. A. (2026). First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Additional efficacy endpoints from the TROPION-Breast02 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1002